Transfer

News

All

Transfer

Public Engagement

Awards & Grants

Diabetes

Stem Cells

Environmental Health

Computational Health

Bioengeineering

Molecular Targets & Therapeutics

Pioneer Campus

6 well plate - cellcuture with medium

Transfer, IDR, VIRO,

Helmholtz Munich contributes to the National Strategy for Gene and Cell Therapies

On June 12, 2024, the National Strategy for Gene and Cell Therapies was unveiled at the Futurium in Berlin.

The X-ray of the human brain closeup image

Transfer, Molecular Targets and Therapeutics, STB,

First Patient Administered New Drug for Brain Tumor Treatment

In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…

Labor Drug Discovery

Transfer, Computational Health,

Helmholtz Munich and Pfizer Join Forces to Advance Target Discovery and Precision Medicine through Deep Learning

In a new collaboration, the Computational Health Center at Helmholtz Munich has teamed up with the global pharmaceutical company Pfizer. The joint initiative, spanning three years, aims to leverage Pfizer's vast knowledge and accumulated data in…

Von links nach rechts: Dr. Konrad Schober (Regierungspräsident Oberbayern), Prof. Ulrike Protzer (Direktorin des Instituts für Virologie bei Helmholtz Munich und an der Technischen Universität München (TUM)), Dr. Michael Frieser (Administrativer Geschäftsführer Helmholtz Munich), Barbara Schretter (Regierungspräsidentin Schwaben), Prof. Klaus Markstaller (Ärztlicher Direktor Universitätsklinikum Augsburg), Prof. Andreas Rathgeber (Vizepräsident Universität Augsburg), Dr. Wolfgang Hübschle (Wirtschaftsreferent Stadt Augsburg), Prof. Martina Kadmon (Dekanin medizinische Fakultät Universität Augsburg), Michael Bungarten (Kaufmännischer Direktor Universitätsklinikum Augsburg), Prof. Claudia Traidl-Hoffman (Direktorin des Helmholtz Munich-Instituts für Umweltmedizin und Professorin für Umweltmedizin an der Medizinischen Fakultät der Universität Augsburg)

Events, Transfer, Environmental Health, Molecular Targets and Therapeutics,

Pandemic Preparedness: New High-Tech Laboratory in Augsburg

EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts

 

On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…

test vitro Hepatitis B HBV to the hand in glove on a blue background

Transfer, Molecular Targets and Therapeutics, VIRO,

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial

TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…

Fork with measuring tape around on pink background

Transfer, HI-MAG, IDO,

Science Has Named GLP-1 Drugs the Breakthrough of the Year

2023 has changed the way we treat obesity. A new class of drugs, mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), is reshaping medicine and improving many people’s lives globally. GLP-1 drugs do not only induce significant weight loss,…